Unione Europea - italiano - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eumedica pharmaceuticals gmbh - associazioni di sulfamidici con trimetoprim, inclusi i derivati - associazioni di sulfamidici con trimetoprim, inclusi i derivati

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - oxaliplatino - oxaliplatino

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

medinova ag - zinci oxidum - cremepaste - zinci oxidum 200 mg, vaselinum album, paraffinum liquidum, alcohol cetylicus 55 mg, polysorbatum 60, sorbitani stearas, isopropylis myristas, decylis oleas, propylenglycolum 50 mg, e 307, butylis parahydroxybenzoas 0.4 mg, e 214 0.4 mg, e 218 3.2 mg, aqua purificata q.s. ad pastam pro 1 g. - dermatite da pannolino, intertrigo, piccole ferite - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

k24 pharmaceuticals s.r.l. - amoxicillina - amoxicillina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

k24 pharmaceuticals s.r.l. - cefazolina - cefazolina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

k24 pharmaceuticals s.r.l. - cefamandolo - cefamandolo

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

k24 pharmaceuticals s.r.l. - cefuroxime - cefuroxime

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

k24 pharmaceuticals s.r.l. - cefaclor - cefaclor

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

k24 pharmaceuticals s.r.l. - benzilpenicillina - benzilpenicillina